C&R Research Inc. (KOSDAQ:359090)
South Korea
· Delayed Price · Currency is KRW 823.00
+29.00 (3.65%)
At close: Mar 6, 2026
C&R Research Revenue
C&R Research had revenue of 15.79B KRW in the quarter ending September 30, 2025, a decrease of -4.04%. This brings the company's revenue in the last twelve months to 63.97B, up 4.50% year-over-year. In the year 2024, C&R Research had annual revenue of 59.69B with 8.32% growth.
Revenue (ttm)
63.97B
Revenue Growth
+4.50%
P/S Ratio
0.72
Revenue / Employee
125.44M
Employees
510
Market Cap
46.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 59.69B | 4.59B | 8.32% |
| Dec 31, 2023 | 55.10B | 6.63B | 13.68% |
| Dec 31, 2022 | 48.47B | 5.30B | 12.28% |
| Dec 31, 2021 | 43.17B | 15.97B | 58.70% |
| Dec 31, 2019 | 27.20B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| WOOJUNG BIO | 37.12B |
| P&K Skin Research Center | 22.13B |
| DT&CRO CO. | 44.36B |
| SLS BIO | 5.47B |
| HLB bioStep | 71.47B |
| BioInfra | 21.92B |
| DreamCIS | 62.06B |
| Curachem | 6.02B |